- Assistant Professor
- Office: 265B
- Phone: 401.874.5320
- Email: Aisling.Caffrey@uri.edu
- Office Location: 7 Greenhouse Road, Kingston, RI 02881
Dr. Caffrey is Director of Outcomes Research for the Rhode Island Infectious Diseases (RIID) Research Program of the Providence Veterans Affairs Medical Center and University of Rhode Island College of Pharmacy, where she is engaged in interdisciplinary infectious diseases research. Dr. Caffrey applies advanced epidemiologic and pharmacoepidemiologic methods to the study of infections caused by dangerous bacterial pathogens. There is a critical need for active comparator trials and comparative effectiveness research in light of present day efforts to increase antimicrobial drug development and extend the life of the current antimicrobial pipeline as multi-drug resistance increases. As such, the objective of her research program is to quantify the benefits and harms of antibiotics in real-world clinical practice.
Comparative Effectiveness Research, Pharmacoepidemiologic Methods, Confounding by Indication, Infectious Disease Epidemiology, Infectious Disease Pharmacoepidemiology, Drug Utilization, Drug Safety, Electronic Health Record Databases, Health Services Research
Director of Outcomes Research, Rhode Island Infectious Diseases (RIID) Research Program, Providence Veterans Affairs Medical Center and University of Rhode Island College of Pharmacy
Post-Doctoral Fellowship, Infectious Disease Pharmacoepidemiology, Department of Veterans Affairs
Ph.D., Pharmacoepidemiology, University of Rhode Island College of Pharmacy
M.S., Epidemiology, State University of New York at Albany School of Public Health
B.A., Pre-Health, Double Major Spanish Linguistics and Psychology, State University of New York at Albany
Caffrey AR. The Role of Comparative Effectiveness Research in Medicine and Health. Medicine and Health, Rhode Island 2012; 95(9): 273-4.
Li E, Greenberg PB, Tseng V, Caffrey AR, Woodmansee SB, Wu WC, Friedmann PD, LaPlante KL. In vitro coagulation effects of ophthalmic doses of bevacizumab. Journal of Ocular Pharmacology and Therapeutics 2012; 28(3):219-21.
Caffrey AR, LaPlante KL. Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Health System, 2002-2009. Infection 2012; 40(3):291-7.
Caffrey AR, Woodmansee SB, Crandall N, Tibert C, Fielding C, Mikolich DJ, Vezeridis MP, LaPlante KL. Low adherence to outpatient pre-operative methicillin-resistant Staphylococcus aureus decolonization therapy. Infection Control and Hospital Epidemiology 2011; 32(9):930-2.
Caffrey AR, Quilliam BJ, LaPlante KL. Risk factors associated with mupirocin resistance in methicillin-resistant Staphylococcus aureus. Journal of Hospital Infection 2010; 76(3):206-10.
Caffrey AR, Quilliam BJ, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2010; 54(10):4394-400. Ranked among most significant publications on infectious diseases pharmacotherapy in 2010. Hirsch EB, Cottreau JM, Ikwuagwu JO, et al. Significant publications on infectious diseases pharmacotherapy in 2010. Am J Health Syst Pharm 2011;68:2075-85.
LaPlante KL, Caffrey AR, Gupta K. Prevention of surgical-site infections. New England Journal of Medicine 2010; 362(16):1540-1; author reply 2-3.
Kogut S, Caffrey A, Pezzullo L. Use of angiotensin-converting enzyme inhibitors / angiotensin receptor blockers and lipid-lowering therapies among Rhode Islanders with diabetes enrolled in Medicare Part D plans in 2006 and 2007. Medicine and Health, Rhode Island 2009; 92(11):373-6.